New imaging agent could reveal prostate cancer treatment success in real time

NCT ID NCT05155046

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This phase 2 trial is testing whether a special PET scan tracer called 18F-DCFPyL can accurately show how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive the tracer and undergo PET/CT scans at several points during treatment. The goal is to see if this imaging method can distinguish between cancer that is responding locally and cancer that has spread, which could help doctors personalize care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-DCFPyL (a radioactive tracer used in PET scans)
What this could lead to
If successful, this imaging method could help doctors quickly see if prostate cancer treatment is working, potentially allowing for earlier adjustments to therapy.
What could go wrong
This is a phase 2 trial with only 130 participants, so results may not apply to everyone. The imaging agent is used for diagnosis, not treatment, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.